We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




MRI Dye Technique Could Detect HIV Dementia

By MedImaging International staff writers
Posted on 07 Mar 2016
Print article
Image: MRI of the brain before (A) and after (B) ferumoxytol injection. A magnified image (C) demonstrates ferumoxytol accumulation (Photo courtesy of the University of Hawaii).
Image: MRI of the brain before (A) and after (B) ferumoxytol injection. A magnified image (C) demonstrates ferumoxytol accumulation (Photo courtesy of the University of Hawaii).
A new magnetic resonant imaging (MRI) contrast dye could be used to target specific white blood cells (WBCs) believed to play a key role in the development of HIV-associated neurocognitive disorders (HAND).

Researchers at the University of Hawaii (Honolulu, USA) are conducting studies to examine the use of ferumoxytol—an ultra-small iron oxide MRI contrast agent—to identify and quantitate monocyte/macrophage (M/MΦ)-mediated inflammation in the brain of HIV-infected people. M/MΦs are believed to play a critical role in the pathogenesis of HAND, but neuroimaging HIV research has not as yet focused on assessing M/MΦ-mediated inflammation in the brain, since no modality exists that can define inflammation extent as a diagnostic tool, or assist in defining objective improvement in clinical trials addressing HAND.

The researchers hypothesized that imaging based on ferumoxytol, which is avidly taken up by circulating M/MΦs, could identify ongoing inflammation resulting from the perivascular M/MΦ, a key pathologic correlate of HAND. The neurocognitive disorders in HIV continue to be prevalent, despite effective combination antiretroviral therapy (cART), and are responsible for a significant impact on morbidity and quality of life. The researchers believe that once M/MΦs have switched on to battle HIV, an unintended consequence is the production of toxic chemicals in the brain that cause uncontrolled inflammation and ultimately cognitive impairment.

“Four HIV-infected subjects with undetectable HIV RNA levels on antiretroviral therapy and cognitive impairment underwent ferumoxtyol-enhanced brain MRI,” wrote lead investigator Neurologist Beau Nakamoto, MD, PhD, in a 2013 study. “On post-ferumoxytol susceptibility-weighted images, all HIV-infected subjects demonstrated a diffuse “tram track” appearance in the perivascular regions of cortical and deep white matter vessels, suggesting ferumoxytol uptake in monocytes/macrophages. This finding was not present in a HIV-seronegative control.”

Related Links:

University of Hawaii


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ceiling-Mounted Digital Radiography System
Radiography 5000 C
DR Flat Panel Detector
1500L
New
X-Ray Detector
FDR-D-EVO III

Print article
Radcal

Channels

Nuclear Medicine

view channel
Image: The new SPECT/CT technique demonstrated impressive biomarker identification (Journal of Nuclear Medicine: doi.org/10.2967/jnumed.123.267189)

New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access

The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.